A detailed history of Two Sigma Investments, LP transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Investments, LP holds 191,315 shares of RLMD stock, worth $535,682. This represents 0.0% of its overall portfolio holdings.

Number of Shares
191,315
Previous 203,261 5.88%
Holding current value
$535,682
Previous $609,000 1.64%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.3 - $4.36 $27,475 - $52,084
-11,946 Reduced 5.88%
191,315 $619,000
Q2 2024

Aug 14, 2024

SELL
$2.93 - $4.94 $69,669 - $117,463
-23,778 Reduced 10.47%
203,261 $609,000
Q1 2024

May 15, 2024

SELL
$3.1 - $6.8 $234,685 - $514,794
-75,705 Reduced 25.01%
227,039 $1.06 Million
Q4 2023

Feb 14, 2024

BUY
$2.45 - $4.22 $258,590 - $445,408
105,547 Added 53.52%
302,744 $1.25 Million
Q3 2023

Nov 14, 2023

SELL
$2.48 - $3.79 $267,068 - $408,141
-107,689 Reduced 35.32%
197,197 $591,000
Q2 2023

Aug 14, 2023

SELL
$2.22 - $3.54 $220,643 - $351,837
-99,389 Reduced 24.58%
304,886 $750,000
Q1 2023

May 15, 2023

SELL
$2.24 - $4.76 $275,266 - $584,942
-122,887 Reduced 23.31%
404,275 $913,000
Q4 2022

Feb 14, 2023

BUY
$2.17 - $35.84 $1.03 Million - $17 Million
475,274 Added 915.96%
527,162 $1.84 Million
Q3 2022

Nov 14, 2022

BUY
$18.3 - $37.02 $741,827 - $1.5 Million
40,537 Added 357.12%
51,888 $1.92 Million
Q2 2022

Aug 15, 2022

BUY
$16.5 - $30.34 $14,041 - $25,819
851 Added 8.1%
11,351 $216,000
Q1 2022

May 16, 2022

BUY
$16.72 - $26.99 $175,560 - $283,395
10,500 New
10,500 $283,000

Others Institutions Holding RLMD

About RELMADA THERAPEUTICS, INC.


  • Ticker RLMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,608,500
  • Market Cap $80.1M
  • Description
  • Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...
More about RLMD
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.